Schedule 13G ownership disclosure
MILESTONE PHARMACEUTICALS IN
Common Shares · CUSIP: 59935V107
Event date: 2025-07-14
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Trails Edge Capital Partners, LP
Shares: 8,847,882.00 · Class: 9.9%
- Trails Edge Biotechnology Master Fund, LP
Shares: 8,847,882.00 · Class: 9.9%
- Ortav Yehudai
Shares: 8,847,882.00 · Class: 9.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001641172-25-020404
- Form type
- SCHEDULE 13G
- Filer
- Milestone Pharmaceuticals Inc.
- CIK
- CIK 1408443
- Filed
- Jul 21, 2025
- Reporting period
- Jul 14, 2025
- Description
- Schedule 13G beneficial ownership